We've found
6,431
archived clinical trials in
Anemia
We've found
6,431
archived clinical trials in
Anemia
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Updated: 12/31/1969
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Pyruvate Kinase Deficiency Natural History Study
Updated: 12/31/1969
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease
Updated: 12/31/1969
Inhaled Mometasone to Promote Reduction in Vasoocclusive Events
Status: Enrolling
Updated: 12/31/1969
Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease
Updated: 12/31/1969
Inhaled Mometasone to Promote Reduction in Vasoocclusive Events
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
Updated: 12/31/1969
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Status: Enrolling
Updated: 12/31/1969
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
Updated: 12/31/1969
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Optimized Erythropoietin (EPO) Treatment
Updated: 12/31/1969
Optimized EPO Treatment of Neonatal Anemia
Status: Enrolling
Updated: 12/31/1969
Optimized Erythropoietin (EPO) Treatment
Updated: 12/31/1969
Optimized EPO Treatment of Neonatal Anemia
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
BioRBC Survival in Adults With Prior Antibody Response to BioRBCs
Updated: 12/31/1969
BioRBC Survival in Adults With Prior Antibody Response to BioRBCs
Status: Enrolling
Updated: 12/31/1969
BioRBC Survival in Adults With Prior Antibody Response to BioRBCs
Updated: 12/31/1969
BioRBC Survival in Adults With Prior Antibody Response to BioRBCs
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
Updated: 12/31/1969
Unfractionated Heparin in Acute Chest Syndrome: A Pilot Feasibility Randomized Controlled Trial of Unfractionated Heparin vs. Standard of Care in Acute Chest Syndrome
Status: Enrolling
Updated: 12/31/1969
Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
Updated: 12/31/1969
Unfractionated Heparin in Acute Chest Syndrome: A Pilot Feasibility Randomized Controlled Trial of Unfractionated Heparin vs. Standard of Care in Acute Chest Syndrome
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
PATient Navigator to rEduce Readmissions
Updated: 12/31/1969
PATient Navigator to rEduce Readmissions
Status: Enrolling
Updated: 12/31/1969
PATient Navigator to rEduce Readmissions
Updated: 12/31/1969
PATient Navigator to rEduce Readmissions
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose
Updated: 12/31/1969
A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE)
Status: Enrolling
Updated: 12/31/1969
IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose
Updated: 12/31/1969
A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Study of Beet Juice for Patients With Sickle Cell Anemia
Updated: 12/31/1969
Phase 2 Study of Effects of Plasma Nitrite in Sickle Cell Anemia
Status: Enrolling
Updated: 12/31/1969
Study of Beet Juice for Patients With Sickle Cell Anemia
Updated: 12/31/1969
Phase 2 Study of Effects of Plasma Nitrite in Sickle Cell Anemia
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials